CRISPR Is Quietly Becoming a Cure Business
Gene editing moved from headlines to clinics: first approved therapies, then a queue of rare-disease cures.
From edit to cure
The first CRISPR therapies target blood diseases with a one-time edit. The pipeline behind them tackles blindness, muscular dystrophy and amyloidosis.
The business model is the twist: one-time cures clash with recurring-revenue pharma economics, forcing new pricing structures.
FAQs
What is "CRISPR Is Quietly Becoming a Cure Business" about?
Gene editing moved from headlines to clinics: first approved therapies, then a queue of rare-disease cures.
Who wrote "CRISPR Is Quietly Becoming a Cure Business"?
"CRISPR Is Quietly Becoming a Cure Business" was written by Demo Admin. Building incoffeed — a daily editorial on tech, AI, fintech and business. Co-founder & editor.
How long does it take to read "CRISPR Is Quietly Becoming a Cure Business"?
9 min — that's the estimated reading time for "CRISPR Is Quietly Becoming a Cure Business" at an average pace.
Where can I find more stories like "CRISPR Is Quietly Becoming a Cure Business"?
More Biotech & Health coverage lives under the “Biotech & Health” topic on incoffeed. You can also react to this story and join the discussion below — the feed keeps serving related reads as you scroll.